Transfusion-associated adverse events incidence and severity after the implementation of an active hemovigilance program with 24 h follow-up. A prospective cohort study. - Bueno JL; Bocanegra AB; Sánchez I; Mateos JM; Puyuelo A; García Erce JA; Villanueva H; Reaño MM; Núñez L; Losa A; Arias A; Aguilar M; et al. (Transfusion, 2023)